Management of Hepatitis B

Hepatitis B is a viral infection caused by the hepatitis B virus (HBV) that primarily affects the liver. The virus can lead to both acute and chronic infections, with chronic cases posing a higher risk for cirrhosis, hepatocellular carcinoma (HCC), and liver failure. The management of hepatitis B encompasses prevention, early diagnosis, antiviral treatment, and ongoing monitoring to prevent complications.

---

1. Acute Hepatitis B Management

Acute hepatitis B is typically self-limiting, with most patients recovering within a few weeks to months without requiring antiviral therapy. However, supportive care and monitoring are essential, especially for severe cases.

Key Steps in Acute Hepatitis B Management

Aspect	Management
Supportive Care	Adequate hydration, nutrition, rest; avoid alcohol and hepatotoxic drugs
Monitoring	Regular liver function tests (LFTs), HBV DNA levels, HBsAg, HBeAg
Hospitalization	Indicated for severe cases (e.g., fulminant hepatitis, coagulopathy, encephalopathy)
Fulminant Hepatitis	May require liver transplantation if there is rapid deterioration

---

2. Chronic Hepatitis B Management

Chronic hepatitis B infection is a long-term condition that requires continuous monitoring and, in some cases, antiviral therapy. Treatment is aimed at reducing viral replication, preventing liver damage, and minimizing the risk of liver failure and HCC.

Phases of Chronic Hepatitis B and Management Approach

Phase	Characteristics	Management
Immune-Tolerant Phase	High HBV DNA (>1 million IU/mL), normal ALT, no liver inflammation	Monitoring; no antiviral therapy
Immune-Active Phase	Elevated ALT, active liver inflammation, high HBV DNA (>2,000 IU/mL)	Antiviral therapy indicated
Inactive Carrier Phase	Low or undetectable HBV DNA, normal ALT, no liver inflammation	Regular monitoring, no immediate therapy
Reactivation Phase	Periodic elevation in ALT and HBV DNA (>2,000 IU/mL)	Consider antiviral therapy

Indications for Antiviral Therapy

Indication	Details
HBeAg-positive hepatitis	HBV DNA > 20,000 IU/mL and elevated ALT
HBeAg-negative hepatitis	HBV DNA > 2,000 IU/mL and elevated ALT
Cirrhosis	Antiviral therapy recommended irrespective of ALT or HBV DNA levels
Prevention of HCC	High-risk groups (e.g., family history of HCC, men > 40 years, women > 50 years)
Pregnant women	HBV DNA > 200,000 IU/mL; antiviral therapy during the third trimester to reduce transmission

---

3. Antiviral Therapy

The main goal of antiviral therapy is to suppress HBV replication, improve liver function, and prevent progression to cirrhosis or HCC.

First-Line Antiviral Agents

Drug	Dosage	Characteristics
Tenofovir Disoproxil Fumarate (TDF)	300 mg once daily	Potent, high barrier to resistance; effective in most patients
Tenofovir Alafenamide (TAF)	25 mg once daily	Similar efficacy to TDF but with better renal and bone safety
Entecavir (ETV)	0.5 mg once daily (1 mg in lamivudine-resistant patients)	Effective with a low risk of resistance; preferred for older patients and those with renal disease

Second-Line Antiviral Agents

Drug	Dosage	Characteristics
Lamivudine (LAM)	100 mg once daily	High resistance rates over time; second-line option
Adefovir Dipivoxil (ADV)	10 mg once daily	Less potent and higher rates of viral resistance

Pegylated Interferon (Peg-IFN) Therapy

Drug	Dosage	Characteristics
Pegylated Interferon (Peg-IFN)	180 mcg subcutaneously once weekly for 48 weeks	Finite therapy duration; potential for HBsAg loss

---

4. Monitoring During Treatment

Regular monitoring is crucial to assess the efficacy of therapy, detect drug resistance, and evaluate for the emergence of complications like cirrhosis or HCC.

Monitoring Parameter	Frequency	Purpose
ALT (LFTs)	Every 3-6 months	Assess for ongoing liver inflammation
HBV DNA levels	Every 3-6 months	Monitor viral suppression and response to treatment
HBeAg/anti-HBe	Every 3-6 months	Monitor for HBeAg seroconversion in HBeAg-positive patients
HBsAg	Annually	Check for HBsAg loss (a marker of viral clearance)
Renal function tests	Annually (if on Tenofovir)	Monitor renal side effects of tenofovir

---

5. Management of Complications

Cirrhosis

Cirrhosis is a common complication of chronic HBV infection, and its management depends on whether the cirrhosis is compensated or decompensated.

Complication	Management
Compensated Cirrhosis	Lifelong antiviral therapy to prevent decompensation
Decompensated Cirrhosis	Antiviral therapy, consideration for liver transplantation
HCC screening	Ultrasound and alpha-fetoprotein (AFP) every 6 months

Hepatocellular Carcinoma (HCC)

HCC is a major concern in patients with chronic HBV, and early detection and treatment are critical.

Treatment	Indication
Surgical resection	Small, localized tumors
Liver transplantation	For advanced cases with cirrhosis or multifocal HCC
Loco-regional therapies	Radiofrequency ablation (RFA), Transarterial Chemoembolization (TACE) for non-surgical candidates

---

6. Special Considerations

Hepatitis B in Pregnancy

Pregnant women with high viral loads require antiviral therapy to reduce the risk of mother-to-child transmission.

Situation	Management
High viral load (>200,000 IU/mL)	Tenofovir (300 mg daily) from the third trimester
Prevention of vertical transmission	Administer HBIG and HBV vaccine to the newborn within 12 hours of birth

Immunosuppressed Patients

Patients on immunosuppressive therapy (e.g., chemotherapy, corticosteroids) are at high risk for HBV reactivation and should receive prophylactic antiviral therapy.

Category	Recommendation
HBsAg-positive patients	Prophylactic antiviral therapy with Tenofovir or Entecavir
Anti-HBc-positive patients	Antiviral therapy if undergoing high-risk immunosuppressive therapy

---

7. Prevention of Hepatitis B

Preventing HBV infection is possible through vaccination and post-exposure prophylaxis.

Strategy	Details
Vaccination	3-dose regimen at 0, 1, and 6 months
Post-exposure prophylaxis	HBIG and HBV vaccine within 24 hours of exposure (e.g., needlestick injury)
Safe practices	Use of sterile needles, safe sex practices

8. Latest Guidelines Overview

The most recent guidelines come from major global health authorities, including:

• American Association for the Study of Liver Diseases (AASLD) 2018 Update
• European Association for the Study of the Liver (EASL) 2017 Guidelines
• World Health Organization (WHO) Guidelines for Hepatitis B (2015)
• Asia Pacific Association for the Study of the Liver (APASL) 2020 Guidelines

These guidelines offer detailed recommendations for the diagnosis, treatment, and monitoring of hepatitis B.

9. Updates in Diagnostic Criteria

The diagnosis of HBV infection is based on a combination of serological markers, HBV DNA levels, and liver function tests. Newer guidelines emphasize:

• FibroScan and Liver Biopsy: These are recommended for assessing liver fibrosis or cirrhosis in chronic HBV infection.
• HBV DNA quantification: Considered essential for guiding treatment decisions, especially in differentiating between immune-active and immune-tolerant phases.

Diagnostic Test	Update
HBsAg	Key marker of infection; should be tested in all suspected cases
HBV DNA Quantification	Essential for determining treatment eligibility
HBeAg/Anti-HBe	Used to classify phase of infection; redefined cutoffs in some guidelines
FibroScan	Non-invasive test for assessing liver fibrosis

10. Indications for Treatment

The decision to start antiviral therapy is now based on a combination of factors, including HBV DNA levels, ALT levels, and the extent of liver damage.

Treatment Criteria According to AASLD and EASL:

Criteria	Recommendation
HBsAg-positive chronic hepatitis B	If HBV DNA > 2,000 IU/mL and ALT elevated, or evidence of fibrosis or cirrhosis
HBsAg-negative (Occult Hepatitis B)	Not typically treated unless HBV DNA is detectable
Cirrhosis (compensated or decompensated)	Antiviral therapy should be initiated irrespective of ALT or HBV DNA levels
HBV DNA >200,000 IU/mL in pregnant women	Antiviral therapy to prevent vertical transmission in the third trimester

11. Antiviral Therapy: Updated Drug Regimens

Recent guidelines prioritize potent agents with a high genetic barrier to resistance. The preferred agents are Tenofovir and Entecavir due to their efficacy and low resistance rates. Additionally, Tenofovir Alafenamide (TAF) has emerged as a newer alternative with a better safety profile, particularly regarding renal and bone side effects.

Antiviral Drug Comparison (2023 Update):

Drug	Dosage	Advantages	Disadvantages
Tenofovir Disoproxil Fumarate (TDF)	300 mg once daily	Highly potent, low resistance	Potential nephrotoxicity, reduced bone mineral density
Tenofovir Alafenamide (TAF)	25 mg once daily	Similar efficacy to TDF but improved renal and bone safety	Costlier option
Entecavir (ETV)	0.5 mg once daily (1 mg if resistant)	Low resistance, effective across multiple patient populations	Limited availability in some regions
Pegylated Interferon (Peg-IFN)	180 mcg weekly for 48 weeks	Finite therapy duration, potential for HBsAg loss	Significant side effects, limited use in cirrhotic patients

12. Updates in Treatment Monitoring

Recent guidelines emphasize more structured monitoring protocols during treatment, particularly focusing on monitoring HBV DNA levels, ALT, and liver function tests every 3-6 months. For patients on long-term therapy, renal monitoring (especially in those on TDF) has been emphasized.

Monitoring Parameter	Frequency	Purpose
HBV DNA levels	Every 3-6 months	Assess treatment efficacy and viral suppression
ALT levels	Every 3-6 months	Assess ongoing liver inflammation
Liver Ultrasound + AFP	Every 6 months in cirrhotic patients	Screening for hepatocellular carcinoma (HCC)
Renal function tests	Annually (for patients on Tenofovir)	Assess for potential renal toxicity

---

Bibliography

1. Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 Hepatitis B Guidance. Hepatology. 2018;67(4):1560-1599.
2. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370-398.
3. World Health Organization. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. World Health Organization; 2015.
4. Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: A 2015 update. Hepatol Int. 2016;10(1):1-98.
5. Seto WK, Lo YR, Pawlotsky JM, Yuen MF. Chronic hepatitis B virus infection. Lancet. 2018;392(10161):2313-2324.
6. Wong GL, Chan HL, Mak CW, et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology. 2013;58(5):1537-1547.